Add time:08/22/2019         Source:sciencedirect.com

BackgroundAllogeneic stem cell transplantation (ASCT) represents the only option with a potential cure rate of 30% to 50% in myelodysplastic syndrome (MDS); however, < 5% of patients are optimal candidates for this management. Therapeutic options are limited in patients unsuitable for ASCT. Evidence that androgens might be beneficial in MDS is controversial. We aimed to document the clinical outcomes of patients diagnosed with MDS treated with danazol as first-line therapy.

We also recommend Trading Suppliers and Manufacturers of Danazol (cas 17230-88-5). Pls Click Website Link as below: cas 17230-88-5 suppliers